Azad, A., Agarwal, N., Armstrong, A. J., Hellmis, E., Schlürmann, F., Sugimoto, M., Ürün, Y., Xing, N., Aregay, M., Lima, J., Meulendijks, D., Chi, K. N. (2025). Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.5_suppl.tps279